MD Anderson Cancer Center: Targeted Therapy Combination Effective for Patients With Advanced Cholangiocarcinoma and BRAF Mutations
August 18, 2020
August 18, 2020
HOUSTON, Texas, Aug. 18 -- The University of Texas's MD Anderson Cancer Center issued the following news release on Aug. 17:
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.
This trial represents the first prospective study for . . .
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.
This trial represents the first prospective study for . . .